US 11,833,130 B2
Treatment of circadian rhythm disorders
Marlene Michelle Dressman, Germantown, MD (US); John Joseph Feeney, Olney, MD (US); Louis William Licamele, Potomac, MD (US); and Mihael H. Polymeropoulos, Potomac, MD (US)
Assigned to VANDA PHARMACEUTICALS INC., Washington, DC (US)
Filed by Vanda Pharmaceuticals Inc., Washington, DC (US)
Filed on Mar. 19, 2021, as Appl. No. 17/206,811.
Application 17/206,811 is a division of application No. 16/792,275, filed on Feb. 16, 2020, granted, now 10,980,770.
Application 16/792,275 is a division of application No. 16/180,316, filed on Nov. 5, 2018, granted, now 10,610,510, issued on Apr. 7, 2020.
Application 14/688,301 is a division of application No. 14/301,799, filed on Jun. 11, 2014, granted, now 9,060,995, issued on Jun. 23, 2015.
Application 16/180,316 is a continuation of application No. 15/382,526, filed on Dec. 16, 2016, granted, now 10,149,829, issued on Dec. 11, 2018.
Application 15/382,526 is a continuation of application No. 14/688,301, filed on Apr. 16, 2015, granted, now 9,539,234, issued on Jan. 10, 2017.
Application 14/301,799 is a continuation of application No. 13/751,011, filed on Jan. 25, 2013, granted, now 8,785,492, issued on Jul. 22, 2014.
Claims priority of provisional application 61/755,896, filed on Jan. 23, 2013.
Claims priority of provisional application 61/738,987, filed on Dec. 18, 2012.
Claims priority of provisional application 61/738,985, filed on Dec. 18, 2012.
Claims priority of provisional application 61/714,149, filed on Oct. 15, 2012.
Claims priority of provisional application 61/650,455, filed on May 22, 2012.
Claims priority of provisional application 61/650,458, filed on May 22, 2012.
Claims priority of provisional application 61/640,067, filed on Apr. 30, 2012.
Claims priority of provisional application 61/590,974, filed on Jan. 26, 2012.
Prior Publication US 2021/0205261 A1, Jul. 8, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/343 (2006.01); A61K 31/00 (2006.01); A61K 45/06 (2006.01); A61K 31/15 (2006.01); A61K 31/277 (2006.01); A61K 31/496 (2006.01); G01N 30/72 (2006.01); G16H 50/20 (2018.01); G01N 33/74 (2006.01); G01N 33/68 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/343 (2013.01) [A61K 9/006 (2013.01); A61K 9/0053 (2013.01); A61K 31/00 (2013.01); A61K 31/15 (2013.01); A61K 31/277 (2013.01); A61K 31/496 (2013.01); A61K 45/06 (2013.01); G01N 30/7233 (2013.01); G01N 33/6893 (2013.01); G01N 33/74 (2013.01); G16H 50/20 (2018.01); G01N 2800/2864 (2013.01)] 10 Claims
 
1. A method for the chronic treatment of Non-24 in a person who is totally blind comprising orally administering to the person a dose of tasimelteon in an amount of 20 to 50 mg once daily about one-half hour to about one-and-one-half hours before the person's desired bedtime.